Literature DB >> 18343843

Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity.

Keith J Chappell1, Martin J Stoermer2, David P Fairlie2, Paul R Young2,1.   

Abstract

The flavivirus NS2B/NS3 protease has received considerable attention as a target for the development of antiviral compounds. While substrate based inhibitors have been the primary focus to date, an approach focussing on NS2B cofactor displacement could prove to be an effective alternative. To understand better the role of the NS2B cofactor in protease activation, we conducted an alanine mutagenesis screen throughout the 42-residue central cofactor domain (NS2B(51-92)) of West Nile virus (WNV). Two sites critical for proteolytic activity were identified (NS2B(59-62) and NS2B(75-87)), where the majority of substitutions were found to significantly decrease proteolytic activity of a recombinant WNV NS2B/NS3 protease. These findings provide mechanistic insights into the structural and functional role that the cofactor may play in the substrate-bound and free protease complexes as well as providing novel sites for targeting new antiviral inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343843     DOI: 10.1099/vir.0.83447-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

1.  Structural and functional parameters of the flaviviral protease: a promising antiviral drug target.

Authors:  Sergey A Shiryaev; Alex Y Strongin
Journal:  Future Virol       Date:  2010-09-01       Impact factor: 1.831

Review 2.  West Nile virus: A re-emerging pathogen revisited.

Authors:  Miguel A Martín-Acebes; Juan-Carlos Saiz
Journal:  World J Virol       Date:  2012-04-12

Review 3.  Functional interplay among the flavivirus NS3 protease, helicase, and cofactors.

Authors:  Kuohan Li; Wint Wint Phoo; Dahai Luo
Journal:  Virol Sin       Date:  2014-03-26       Impact factor: 4.327

4.  Ligand-bound structures of the dengue virus protease reveal the active conformation.

Authors:  Christian G Noble; Cheah Chen Seh; Alexander T Chao; Pei Yong Shi
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

5.  Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction.

Authors:  Zhong Li; Matthew Brecher; Yong-Qiang Deng; Jing Zhang; Srilatha Sakamuru; Binbin Liu; Ruili Huang; Cheri A Koetzner; Christina A Allen; Susan A Jones; Haiying Chen; Na-Na Zhang; Min Tian; Fengshan Gao; Qishan Lin; Nilesh Banavali; Jia Zhou; Nathan Boles; Menghang Xia; Laura D Kramer; Cheng-Feng Qin; Hongmin Li
Journal:  Cell Res       Date:  2017-07-07       Impact factor: 25.617

6.  Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B-NS3 proteinase of West Nile virus.

Authors:  Sergey A Shiryaev; Ilian A Radichev; Boris I Ratnikov; Alexander E Aleshin; Katarzyna Gawlik; Boguslaw Stec; Christian Frisch; Achim Knappik; Alex Y Strongin
Journal:  Biochem J       Date:  2010-04-14       Impact factor: 3.857

7.  Mutagenesis of D80-82 and G83 residues in West Nile Virus NS2B: effects on NS2B-NS3 activity and viral replication.

Authors:  Fan Jia; Jingjing Fan; Bo Zhang; Zhiming Yuan
Journal:  Virol Sin       Date:  2013-01-16       Impact factor: 4.327

8.  NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease.

Authors:  Xun-Cheng Su; Kiyoshi Ozawa; Ruhu Qi; Subhash G Vasudevan; Siew P Lim; Gottfried Otting
Journal:  PLoS Negl Trop Dis       Date:  2009-12-08

9.  Analysis of Protein-Protein Interactions by Split Luciferase Complementation Assay.

Authors:  Yuekun Lang; Zhong Li; Hongmin Li
Journal:  Curr Protoc Toxicol       Date:  2019-12

Review 10.  The flavivirus protease as a target for drug discovery.

Authors:  Matthew Brecher; Jing Zhang; Hongmin Li
Journal:  Virol Sin       Date:  2013-11-14       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.